<DOC>
	<DOC>NCT01687582</DOC>
	<brief_summary>The aim of the study is to evaluate after 4 to 6 months the effects of a GLP-1 analog treatment on psoriatic skin lesions in patients with type 2 diabetes.</brief_summary>
	<brief_title>Effect of GLP-1 Analogs on Psoriasis in Type 2 Diabetic Patients</brief_title>
	<detailed_description>The objective of this study is to analyse short and medium-term efficacy on clinical, immunological and histopathological parameters of a GLP-1 receptor agonist on moderate to severe psoriasis plaques in a group of patients with type 2 diabetes.</detailed_description>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Glucagon-Like Peptide 1</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<mesh_term>Exenatide</mesh_term>
	<mesh_term>Glucagon</mesh_term>
	<criteria>Type 2 diabetic patients treated with oral antihyperglycaemic agents and/or insulin and presenting stable psoriasis plaques for at least one year, which failed to respond to previous systemic and/or topical treatments. Type 1 diabetes Secondary diabetes Liver, renal or pancreatic disease Previous treatment with GLP1 agonist or DPP4 inhibitors agents</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>type 2 diabetes</keyword>
	<keyword>psoriasis</keyword>
	<keyword>exenatide</keyword>
	<keyword>liraglutide</keyword>
</DOC>